Skip to content
lifestyle.mmminimal.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Saol Therapeutics
Saol Therapeutics Announces Completion of Enrollment in Pivotal Phase III BEACON Trial of SL1002 for the Treatment of Chronic Pain Related to Osteoarthritis of the Knee
October 8, 2026
Saol Therapeutics Announces Strategic Investment of Up to $115 Million from Oaktree to Support Launch Preparation for SL1009
September 15, 2026
Saol Therapeutics Announces the Acceptance of Resubmission of SL1009 (DCA) by the FDA with PDUFA Date of Dec. 30, 2026
July 28, 2026
Saol Therapeutics Resubmits the New Drug Application for SL1009 (DCA) for the Treatment of Pyruvate Dehydrogenase Complex Deficiency (PDCD), an Ultra-Rare Disease
July 7, 2026